Ginkgo Bioworks Holdings (DNA) Revenue Growth (3y) (2023 - 2026)

Ginkgo Bioworks Holdings (DNA) Revenue Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue Growth (3y) (Qtr)
1 Oculis Holding AG 65,538.84 Bn 65,538.56 Bn - -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn - -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn - -
4 BeOne Medicines 469.46 Bn 464.67 Bn 1.35 Bn 50.07%
5 Vertex Pharmaceuticals 122.69 Bn 115.45 Bn 2.59 Bn 7.94%
6 Regeneron Pharmaceuticals 70.41 Bn 61.65 Bn 3.31 Bn 4.47%
7 Belite Bio 62.84 Bn 62.84 Bn - -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn 79.44%
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn 54.05%
10 Ginkgo Bioworks Holdings 441.96 Mn 298.10 Mn 16.38 Mn -37.74%

Historic Data

Download Data
DateValue
Mar 31, 2026 -37.74%
Dec 31, 2025 -30.22%
Sep 30, 2025 -16.37%
Jun 30, 2025 -30.00%
Mar 31, 2025 -39.00%
Dec 31, 2024 -33.41%
Sep 30, 2024 4.69%
Jun 30, 2024 8.80%
Mar 31, 2024 -4.89%
Dec 31, 2023 96.46%
Sep 30, 2023 60.92%